Hanmi Pharm Co Ltd

ESG Report

Report overview

The report presents Hanmi Pharm's consolidated 2024 sales of KRW 1.4955 trillion and detailed Scope 1, 2 and 3 emissions. It describes a 30% GHG reduction target against 2018 by 2030 and a Scope 1 and 2 net-zero goal for 2040. The company also reports conducting double materiality assessments since 2022, expanding the assessment to consolidated subsidiaries in 2024. ESG governance includes annual board oversight and CEO-led CSR and hEHS committees.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 1 May 2025
Language
Pages
File size
Restatement: Disclosed

Standards & Assurance

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level
CDP score

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

ESG & Materiality

ESG data

Indicators available in this report:

Scope 1 emissions
Scope 2 emissions
Scope 3 emissions
Energy consumption
Water consumption
Waste
Employees
Women on the board
Women in management
Workplace fatalities
Net zero target

Materiality

Assessment
Basis
Matrix

Build your research dataset.

Original reports, structured indicators and machine-readable Markdown, tailored to your project.

Explore our services